← Leaderboards
Manu Kohli
University Of Arkansas Med Scis Ltl Rock
$73,485
Attributed
$73,485
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $33.4K · FY2005–06$50K$37.5K$25K$12.5K$0
'05
'06
Funding mix
By agency
NIH$73,485 · 3
By mechanism
M01$73,485 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Arkansas Med Scis Ltl Rock
Same institution · by research overlap
- Martin Hauer-Jensen$11,801,523
- Bart Barlogie$10,937,441
- Stavros C. Manolagas$5,168,384
- Richard R Drake$9,503,019
- Timothy C Chambers$3,739,446
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectPatient Oriented ResearchProstate NeoplasmsHuman Therapy EvaluationChemopreventionClinical ResearchDosageEstradiolHormone TherapyMaleNeoplasm /Cancer ChemotherapyOsteoporosisRacial /Ethnic DifferenceTherapy Adverse EffectAnticoagulantsThrombosisBiomarkerBlood CoagulationClinical Trial Phase IClinical TrialsDisease /Disorder Prevention /Control
Grant awards (5)
TRIAL OF OSTEOPOROSIS PREVENTION IN RACIALLY DIVERSE PROSTATE CANCER PATIENTS$4,297
M01 · FY2006 · RR · contact PI
TRIAL OF OSTEOPOROSIS PREVENTION IN RACIALLY DIVERSE PROSTATE CANCER PATIENTS$32,740
M01 · FY2005 · RR
UARK 2000-35, PHASE I TRIAL OF THE EFFECTS OF PARENTERAL ESTROGEN THERAPY$617
M01 · FY2005 · RR
Phase I Trial of the Effects of Estrogen Therapy$19,143
M01 · FY2004 · RR
Osteoporosis prevention in prostate cancer patients$16,688
M01 · FY2004 · RR